NCT04034368Unknown4 期
A Perspective Study of the Antiviral Efficacy and Safety of Switching to TAF Treatment in CHB Adults With Suboptimal Response (SOR) or Intolerant to Entecavir
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 8
- 主要终点
- Main efficacy endpoint
研究概览
简要总结
This is a multicenter, single arm, open label, historical control pilot Study to the antiviral efficacy and safety of Suboptimal Responders to Entecavir Switching to TAF Treatment at week 48 (investigate the rates of complete virological response on switching to TAF in patients with Suboptimal response or ETV intolerance to standard ETV= 0.5 mg monotherapy).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures;
- •Male and female subjects,18 years of age and older, based on the date of the screening visit;
- •Suboptimal Responders to Entecavir (defined as CHB patients treated with at least 12 months of ETV 0.5mg QD with prior suboptimal response viral load still detectable at week 48).
- •ETV intolerance population (defined as unwilling or poor adherence to administer ETV in fasting food, renal impairment with ETV dosage adjustment required, pts with other unidentified reasons willing to switch, etc);
- •Screening serum ALT level ≤ 10 × ULN;
- •Normal ECG (or if abnormal, determined by the Investigator not to be clinically significant);
- •Must be willing and able to comply with all study requirements.
排除标准
- •Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study;
- •Co-infection with HCV, HIV, or HDV;
- •Any history of, or current evidence of, clinical hepatic decompensation (i.e., moderate-severe ascites, encephalopathy or variceal hemorrhage);
- •Evidence of hepatocellular carcinoma (e.g. as evidenced by recent imaging);
- •Abnormal hematological and biochemical parameters, including: Hemoglobin < 10 g/dl, Absolute neutrophil count < 0.75×109/L, Platelets ≤ 50×109/L, AST or ALT > 10 × ULN, Total bilirubin > 2.5 × ULN, Albumin < 3.0 g/dl, INR > 1.5 × ULN;
- •Received solid organ or bone marrow transplant;
- •Recent history of pancreatitis (within 24 weeks prior to the first dose of study medication);
- •Evidence of other autoimmune or metabolic liver diseases (except non-alcoholic fatty liver disease);
- •Significant renal, cardiovascular, pulmonary, or neurological disease in the opinion of the investigator;
- •Malignancy within the 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection(basal cell skin cancer, etc). Subjects under evaluation for possible malignancy are not eligible;
- •Known hypersensitivity to study drugs, metabolites, or formulation excipients;
- •Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance;
- •Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.
研究组 & 干预措施
Experimental Arm
Experimental
Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
干预措施: Tenofovir Alafenamide (TAF) (Drug)
结局指标
主要结局
Main efficacy endpoint
时间窗: Week 48
The primary efficacy endpoint is the proportion of subjects with plasma HBV DNA levels below 20 IU/ml at Week 48.
次要结局
- Key secondary efficacy endpoint(Week 48)
研究者
Yanhang Gao
Professor
The First Hospital of Jilin University
相似试验
Unknown
4 期
A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected PatientsHIVNCT00199121Johann Wolfgang Goethe University Hospital
终止
4 期
Immune Reconstitution in naïve HIV Patients With CD4 <100 Cells/mL When Treated With Lopinavir or Efavirenz.HIV InfectionNCT00386659Hospital Clinic of Barcelona60
Unknown
4 期
Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected PatientsHIV-1 Adults PatientsAIDSTriple Class FailureNCT01013987Fundación Huésped60
已完成
3 期
Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve PatientsHIV InfectionNCT00234923Abbott138
已完成
不适用
Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in GermanyHIV InfectionsNCT03754803ViiV Healthcare376